Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
May 01 04:00PM ET
0.1930
Dollar change
-0.0020
Percentage change
-1.03
%
Index- P/E- EPS (ttm)-1.03 Insider Own43.07% Shs Outstand35.52M Perf Week22.23%
Market Cap6.90M Forward P/E- EPS next Y-0.63 Insider Trans0.00% Shs Float20.34M Perf Month-61.32%
Income-16.75M PEG- EPS next Q-0.28 Inst Own5.92% Short Float7.03% Perf Quarter-75.87%
Sales0.00M P/S- EPS this Y45.66% Inst Trans-85.96% Short Ratio1.46 Perf Half Y-90.54%
Book/sh-0.23 P/B- EPS next Y32.98% ROA-63.34% Short Interest1.43M Perf Year-98.11%
Cash/sh0.06 P/C3.36 EPS next 5Y- ROE-115.44% 52W Range0.14 - 13.79 Perf YTD-87.22%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-98.60% Beta0.57
Dividend TTM- Quick Ratio0.42 Sales past 5Y-50.00% Gross Margin- 52W Low34.49% ATR (14)0.10
Dividend Ex-Date- Current Ratio0.42 EPS Y/Y TTM-2064.71% Oper. Margin0.00% RSI (14)35.55 Volatility30.59% 32.78%
Employees41 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price3.25
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q11.53% Payout- Rel Volume1.05 Prev Close0.19
Sales Surprise- EPS Surprise-12.20% Sales Q/Q- EarningsMar 15 AMC Avg Volume978.20K Price0.19
SMA20-42.88% SMA50-64.35% SMA200-94.02% Trades Volume1,028,193 Change-1.03%
Date Action Analyst Rating Change Price Target Change
Nov-22-23Initiated H.C. Wainwright Buy $11
Oct-09-23Initiated Robert W. Baird Outperform $9
Today 07:00AM
Apr-23-24 07:00AM
Apr-19-24 04:05PM
Apr-16-24 08:31AM
Apr-09-24 07:00AM
04:05PM Loading…
Mar-15-24 04:05PM
Mar-11-24 07:00AM
Feb-12-24 07:00AM
Jan-08-24 07:00AM
Dec-13-23 07:00AM
Dec-12-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 04:05PM
Nov-03-23 07:00AM
Nov-01-23 07:00AM
07:00AM Loading…
Oct-30-23 07:00AM
Oct-10-23 07:00AM
Sep-13-23 05:50AM
Sep-11-23 04:05PM
Aug-24-23 12:06PM
Aug-22-23 11:41AM
Aug-16-23 06:00AM
Aug-07-23 05:00AM
Jun-23-23 05:00AM
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.